Stereotaxis (OTCMKTS:STXS) and Semler Scientific (OTCMKTS:SMLR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, dividends and valuation.

Insider and Institutional Ownership

23.1% of Stereotaxis shares are held by institutional investors. Comparatively, 12.3% of Semler Scientific shares are held by institutional investors. 38.1% of Stereotaxis shares are held by insiders. Comparatively, 13.9% of Semler Scientific shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings for Stereotaxis and Semler Scientific, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Stereotaxis 0 0 0 0 N/A
Semler Scientific 0 0 2 0 3.00

Semler Scientific has a consensus target price of $44.00, suggesting a potential upside of 4.76%. Given Semler Scientific’s higher probable upside, analysts plainly believe Semler Scientific is more favorable than Stereotaxis.

Profitability

This table compares Stereotaxis and Semler Scientific’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Stereotaxis 0.40% 6.57% 0.59%
Semler Scientific 23.33% 385.99% 82.47%

Earnings & Valuation

This table compares Stereotaxis and Semler Scientific’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Stereotaxis $29.35 million 4.04 $120,000.00 N/A N/A
Semler Scientific $21.49 million 12.37 $5.01 million $0.66 63.64

Semler Scientific has lower revenue, but higher earnings than Stereotaxis.

Volatility & Risk

Stereotaxis has a beta of 2.15, indicating that its stock price is 115% more volatile than the S&P 500. Comparatively, Semler Scientific has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500.

Summary

Semler Scientific beats Stereotaxis on 7 of the 11 factors compared between the two stocks.

About Stereotaxis

Stereotaxis, Inc. designs, manufactures, and markets robotic systems and instruments for the treatment of abnormal heart rhythms in the United States and internationally. Its products include Niobe ES robotic system that enables physicians to complete interventional procedures by providing image guided delivery of catheters and guide wires through the blood vessels and chambers of the heart to treatment sites; and Vdrive system, which offers navigation and stability for the diagnostic and therapeutic devices designed to enhance interventional procedures. The company also offers Odyssey solution, a real-time information solution to manage, control, record, and share procedures across networks. In addition, it provides disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company's disposables and other accessories include V-CAS and V-CAS Deflect catheter advancement systems; and V-loop circular and V-Sono ICE catheter manipulators. The company markets its products through direct sales force, distributors, and sales agents. Stereotaxis, Inc. was founded in 1990 and is headquartered in St. Louis, Missouri.

About Semler Scientific

Semler Scientific, Inc. develops, manufactures, and markets patented products that assist healthcare providers to evaluate and treat patients with chronic diseases in the United States. Its products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition; and WellChec, a multi-test service platform to evaluate patients with various chronic diseases. The company's products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, and family practitioners, as well as organizations, including healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry; and other healthcare organizations, such as risk assessment groups and other home healthcare providers. It offers its products through salespersons and distributors. Semler Scientific, Inc. was founded in 2007 and is headquartered in San Jose, California.

Receive News & Ratings for Stereotaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stereotaxis and related companies with MarketBeat.com's FREE daily email newsletter.